CCL17 and hepatocellular carcinoma: TAMs were reported to induce tumor progress via the CCR4-CCL17 axis in hepatocellular cancer, the CCR4-CCL22 axis in prostate cancer [33,34], and CCL22 in esophageal squamous-cell carcinoma [48].